Enkay Therapeutics Secures Two Shanghai Municipal Science and Technology Project Grants for CAR-NK Cell Therapy Development

Dec 12, 2024 08:00 CST Updated 08:00

NK CellTech

Immune Cell Therapy Developer

Recently，Shanghai Science and Technology Commission Releases "Notice on the 2024 Shanghai Annual 'Science and Technology Innovation Action Plan' Cell and Gene Therapy Special Project Approval" and "Notice on the 2024 Shanghai Annual 'Science and Technology Innovation Action Plan' SME Technology Innovation Fund Proposed Projects." Enke Biopharm's research project, "Development and Safety of Novel CAR-NK Cell Products Targeting Solid Tumors,""Efficacy Evaluation" and "Preclinical and Clinical Research of Gene-Modified NK Cell Products" were respectively supported for project initiation.

Enkaicell Continues to Receive Support from Shanghai Project Funds, Demonstrating the Company's Strong Scientific Research Capabilities and Innovative Technical Expertise in the Field of NK Cell Therapy, as Well as Reflecting Its Leading Position in This Area. Enkaicell Will Continue to Increase Investment in Scientific Research, Actively Promote the Application and Transformation of Research Achievements, and Is Committed to Bringing Innovative NK Cell Therapies to Market as Soon as Possible to Better Serve Patients.

Exterior of Enka Pharmaceutical Company

Shanghai Enke Cell Technology Co., Ltd. (Enke Saiyao) is a company focused on research and development.NKA biotechnology company specializing in innovative cell therapy technologies. Based on the team30More than ... yearsNKBasic cell biology, preclinical and clinical translational exploration research, NKCell Therapeutics is committed to becoming a leader inNKA world-leading cell therapy company with a deep understanding of cell therapy and its cutting-edge technologies.

Enkaissai Medicine has exclusive allogeneic peripheral blood.NKCell Expansion and Cryopreservation for Clinical "Off-the-Shelf" GradeABCDE-NK^®Industrial Production Platform(Single Blood Supply OnceNKCell yield can reach trillions.)Based on, withNKCell-specific recognition of tumor receptors/Ligand Target Mining Technology(NKR-NK^TM)Relying on, Through logic gate gene circuits and other synthetic immunology chassis technologies (SynNK^TM), to achieveNKCellular Pluripotency-Intelligentization-Controllable gene editing, enabling precise targeting of cancer cells, precise adaptation to the tumor microenvironment, and precise matching of donor-recipient effects./Target cells.2024Year, Enke Pharmaceutical has had2IndividualNKCell products have successively obtained approval in the United StatesFDAAnd ChinaCDEClinical Trial(IND)Permission.

Enkaice Pharmaceuticals will focus on addressing the treatment challenges of major clinical diseases (such as cancer, autoimmune diseases, aging and degenerative diseases, immunodeficiency and related conditions), with the goal of achieving precise immunotherapy, and has developed a series of original intelligent solutions.NKCellular products, aiming to create an immune cell drug enterprise that continuously breaks through core technologies and maintains international leadership, building a new generation globally.NKThe birthplace of cell therapy technologies and products.